Novartis's Beovu Meets Phase-3 Primary Endpoint
December 15 2020 - 1:09AM
Dow Jones News
By Joshua Kirby
Novartis AG said Tuesday that its drug Beovu showed positive
results in the Phase-3 KESTREL study, with the trial meeting its
primary endpoint.
Beovu, a treatment for diabetic macular edema, met the primary
endpoint of non-inferiority in change in best-corrected visual
acuity from aflibercept 2 mg after a year, the Swiss pharmaceutical
company said. The trial also met its key secondary endpoint of
non-inferiority in average change in BCVA at week 40 through week
52 of the trial, Novartis said.
The findings from this and a previous trial will be submitted to
health authorities in the first half of next year, the company
added.
Write to Joshua Kirby at joshua.kirby@dowjones.com;
@joshualeokirby
(END) Dow Jones Newswires
December 15, 2020 01:54 ET (06:54 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2024 to May 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From May 2023 to May 2024